[Value of PSA density determination in prostate carcinoma]

Area of Science:

• Urology
• Oncology
• Biochemistry

Context:

• Prostate cancer diagnosis relies on serum Prostate-Specific Antigen (PSA) levels.
• PSA density (PSAD), calculated using prostate specimen weight/volume, is investigated as a supplementary diagnostic marker.
• Established cut-off values, like 0.15 ng/ml/g, guide cancer suspicion.

Purpose:

• To evaluate the clinical utility of PSA density (PSAD) in patients with varying serum PSA levels for diagnosing prostate cancer.
• To determine if PSAD provides significant additional information beyond serum PSA, particularly in borderline ranges.

Summary:

• The study analyzed 98 prostate cancer patients, calculating PSAD from radical prostatectomy specimens.
• In patients with serum PSA < 10 ng/ml (n=33), PSAD values below 0.15 were common, suggesting a low risk.
• Sixty-one of 65 patients with PSA > 10 ng/ml had PSAD > 0.15, aligning with cancer suspicion.

Impact:

• PSAD determination provides minimal additional diagnostic information for prostate cancer in patients with serum PSA levels below 10 ng/ml.
• Routine PSAD measurement is not recommended for risk stratification in this patient group.
• Findings suggest focusing diagnostic efforts on other parameters when serum PSA is < 10 ng/ml.